Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Sclerosis, Relapsing”

987 trials

Showing 20 of 987 results

Large-scale testing (Phase 3)Study completedNCT02753088
What this trial is testing

Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Biocad 158
Not applicableUnknownNCT05519553
What this trial is testing

Peer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-remitting
Nantes University Hospital 60
Testing effectiveness (Phase 2)Study completedNCT01864148
What this trial is testing

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Who this might be right for
Multiple Sclerosis
Biogen 419
Not applicableEnrolling By InvitationNCT06001138
What this trial is testing

Multiple Sclerosis: FutureMS-2 - an Observational Cohort and Scottish Precision Medicine Study

Who this might be right for
Multiple Sclerosis
University of Edinburgh 440
Not applicableStudy completedNCT04220814
What this trial is testing

Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Rennes University Hospital 94
Not applicableStudy completedNCT03718247
What this trial is testing

Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University of Virginia 45
Post-approval studies (Phase 4)Study completedNCT04869358
What this trial is testing

Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab

Who this might be right for
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals 34
Testing effectiveness (Phase 2)Study completedNCT02097849
What this trial is testing

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Who this might be right for
Relapsing Forms of Multiple Sclerosis
Biogen 71
Not applicableStudy completedNCT00206635
What this trial is testing

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Bayer 432
Large-scale testing (Phase 3)Active Not RecruitingNCT04926818
What this trial is testing

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis (MS)
Novartis Pharmaceuticals 129
Post-approval studies (Phase 4)Study completedNCT04261790
What this trial is testing

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Johns Hopkins University 10
Large-scale testing (Phase 3)Study completedNCT01838668
What this trial is testing

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-Remitting Multiple SclerosisMultiple Sclerosis
Biogen 225
Early research (Phase 1)Study completedNCT01738347
What this trial is testing

Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).

Who this might be right for
Relapsing-remitting Multiple Sclerosis (rrMS)
GE Healthcare 30
Post-approval studies (Phase 4)Active Not RecruitingNCT05090371
What this trial is testing

Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Novartis Pharmaceuticals 136
Early research (Phase 1)Study completedNCT00103974
What this trial is testing

Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Bayhill Therapeutics 30
Not applicableStudy completedNCT05684016
What this trial is testing

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
George Washington University 75
Large-scale testing (Phase 3)Study completedNCT04788615
What this trial is testing

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 185
Not applicableStudy completedNCT01628315
What this trial is testing

Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study

Who this might be right for
Multiple Sclerosis, Relapsing-remitting
University at Buffalo 159
Post-approval studies (Phase 4)Study completedNCT01534182
What this trial is testing

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Novartis Pharmaceuticals 298
Post-approval studies (Phase 4)UnknownNCT03424733
What this trial is testing

Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects

Who this might be right for
Multiple Sclerosis
Holy Name Medical Center, Inc. 50
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation